Biogen Idec and Eisai said they will collaborate on and co-market two of Eisai's clinical candidates for Alzheimer's disease.
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.
Bayer bought China-based Dihon Pharmaceutical Group, which specializes in traditional Chinese medicine consumer goods.
The drugmaker says the voluntary measure was out of an abundance of caution.
The agency says is it time to update the onerous decades-old review process.
Bloomberg reports that Teva has sparked interest as a takeover target.
Germany's price transparency requirement has the industry worried other markets will demand lower prices.
The drugmaker, hitherto known for its generic expertise, says the purchase could mean that half its future revenue will come from branded, specialty drugs.
Merck announced this week that its insulin glargine biosimilar, being developed with Samsung and Biogen Idec, would soon enter Phase-III trials.
The CEO told Leerink analysts the pharma business needs better margins, not unfettered R&D budgets.
Driven by a number of high-profile buys in 2013, pharma saw a return to investment through acquisition after a 2012 dip.
The new manufacturing site will be its first in Asia.
A panel is meeting February 10 to discuss revoking the OTC status of some medications.
The suit stalls Eli Lilly's biosimilar version of insulin glargine.
168 employees will be pink-slipped this quarter.
Amgen 2013 revenues increased by 17% from 2012 to $18.7 billion, the company reported, but it faces headwinds in 2014 for older meds.
Taken to new heights on the launch of MS blockbuster Tecfidera, the drug maker has raised its 2014 forecast.
Generics took a $2.2-billion bite out of sales, but growth products like Gilenya helped to minimize the impact.
The news follows company statements that China is not business friendly.
Prescription data shows Gilead's Sovaldi is winning prescriptions at a faster rate than Vertex's Incivek did at launch.
The company will be beefing up support of Sandoz, its generics division.
The latest IMS report shows that 50% of the top 50 pharma companies are not on social media. Executive Director Murray Aitken tells MM&M it is to pharma's detriment.
Analyst Seamus Fernandez, of Leerink Partners, says the drugmaker is set to be a considerable immuno-oncology and respiratory presence.
Herve Hoppenot changed jobs overnight.
The company bought rights to a Phase-II drug for recurrent migraine headaches.
The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.
An insider says Merck may be up for trading its OTC business for Novartis's animal health business, but the benefits for either side may be better on paper.
Erez Vigodman will be Teva's president and CEO as of February 11.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
Cambridge, MA-based Epizyme claimed $29 million in milestone payments from the two drugmakers.
The company's guidance aligns with expectations that 2014 will be a nail-biter.
Two months after it was pulled from the US market, Iclusig is returning with a narrower approval.
The $2.9 billion deal means Bayer owns prostate cancer drug Xofigo in full.
The American College of Cardiology is contributing its Pinnacle registry to identify clinical trial patients.
BMS is giving up its stake of the AstraZeneca diabetes joint venture for $2.7 billion up front, and future milestone payments.
Teva said a settlement will allow it to sell a copy of the blockbuster ED pill prior to the official LOE.
Biogen Idec and JV partner Samsung are going into the biosimilars business.
The FDA's Center for Drug Evaluation and Research released a preliminary year-in-review report that says the agency has cleared 26 new molecular entities this year.
Vaccine LU AF20513 is the their third Alzheimer's collaboration.
The company released two financial scenarios. The key is generic Copaxone.
Covidien is buying ingestible-camera company Given Imaging.
The drug is priced at $28,000 a month, before add-ons like ribavirin and (possibly) interferon.
The drug failed to hit its Phase III targets.
Novo's global diabetes study finds that only 29% of polled patients were asked what they thought about prescribed regimens.
Chronic disease patients seek online support and information, and show little love for branded websites.
Forest's cost-savings initiative is aimed at reducing operating expenses by $500 million, while Eisai said it's cutting 130 positions in the US and Europe.
Spectrum DNA says its genetic services are at the ready, even if 23andMe's are not.
The leukemia drug is staying on the market, but for a more restricted patient population.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
Actavis shrinks its staff by 30%, and Bayer reduces its California footprint.
The agency's bad-ad warning letter calls the new violations "particularly troubling."
The patient population is small, at around 3,000, but the expected price tag is $330,000 a year.
Early clinical trial results indicate 81% of advanced melanoma patients survived for one year.
The catch is the difference between sales and revenues. Generics will continue to be a force, and small-audience drugs will become increasingly important.
Known as Breo Ellipta in the US, GlaxoSmithKline's Relvar Ellipta was approved by the EMA for asthma and COPD. The overall market is expected to continue to grow, but an NIH study indicates more patient conversations need to happen.
The US-only recall amounts to less than 1% of the company's inventory.
The current number is reported to hover around $4 billion.
The company says it will cut staff and costs, focus on big accounts and try to keep sales reps from leaving.
An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.
The company announced the layoffs Friday.
The FDA's Bad Ad group says the drugmaker misbranded its cholesterol drug during interviews on CNBC.
The company's pursuit of a tighter research focus follows a path very much like that of its peers.
A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
The "New Endo" will be one company on the outside, two on the inside.
The news is part of an ongoing reorg by the Swiss firm that is rumored to include selling off its animal health business.
A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.
Generic giant Teva refuted allegations that the CEO, Jeremy Levin, and the board of directors were at odds over the company's cost-saving maneuvers.
The company's hep. C drug Incivek peaked in 2011. Competition and pipeline drugs have forced the company to regroup.
The prostate cancer drug company is reportedly seeking a buyer to turn things around.
Based on its first three months on market, Tecfidera is one launch that's living up to its hype.
A court refuses to compel a government agency to schedule the firm's epilepsy drug, as the med's patent clock ticks.
The company says it is moving its Januvia sales pitch from defending market share to expanding it.
Vyvanse was one of six drugs with double-digit revenue increases, propelling sales of the specialty drugmaker Shire up 13% for the quarter.
A roundup of firms' quarterly performance culled from sources around the web.
Amid talk of cost containment, Lilly said it's also enjoying nice returns from some of its older diabetes drugs.
Word came of Breakthrough Designation for an HCV hopeful, a day after a hiccup in a heart drug trial.
BMS is showing signs of emerging from the cliff, but doubt lingers on Eliquis's slow launch in a post-Plavix marketplace.
Eli Lilly CEO John Lechleiter says he's not ready to cut his firm's $5.3-billion R&D budget just yet.
Lantus-like rivals can expect a wary reception from endocrinologists, even if these biosimilars reach market, researchers predict.
Eisai, the marketing half of the Arena-Eisai collaboration, plans to double the sales force by December.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
The drug maker is beefing up its MedImmune offerings with a $440-million acquisition and a deal with ADC Therapeutics.
The drug maker is giving its inhaled insulin another go.
The Swiss biopharma is increasing capacity and investing $800 million in four locations.
The generics giant said it will lay off about 5,000 employees as it braces for the expiry of one of its specialty brands.
An analyst notes that early Phase III results in a psoriasis clinical trial could change the drug's efficacy profile. It could also fill out the financial potential of a standalone innovative unit, should Pfizer divide.
Three former workers are accused of giving proprietary data to a drug company abroad.
The group's offices will be in the DuBiotech research cluster.
The drug maker says it is accelerating development of new drugs and focusing on expanding indications of current ones.
A roundup of news related to hepatitis C.
The company it putting close to $4 billion towards developing pills that can replace insulin injections.
The CEO says Sanofi's patent-loss turnaround is coming.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
Echoing a strategy similar to that posed by Merck, the drug maker told investors that its strategy for hitting revenue targets includes efficiencies. It also depends on a regulatory-friendly pipeline.
The FDA approved the drug maker's depression drug Brintellix, one day after the Danish company announced a reorg that includes shifting 180 to 200 jobs.
The company will "fill the bag" of its sales reps, as part of a reorganization that also includes 8,500 job cuts and a more refined R&D focus.
Eli Lilly is the first Big Pharma to team up with the agency in its rare-disease pre-clinical development program.
Price, market potential and emotional pull make this subcategory of orphan diseases one to watch, an analyst writes. Hint: it's not oncology.